Needham Initiates Coverage On Phathom Pharmaceuticals with Buy Rating, Announces $40 Price Target

Needham initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy rating and a $40 price target.

Benzinga · 11/19/2019 13:54

Needham initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy rating and a $40 price target.